For Canadian researchers working with Retatrutide through Red Fox Peptides, the 48-week timeframe represents a genuine commitment, but one supported by a clear data trajectory from day one
Peptide or compound Primary category What researchers study Status context Semaglutide GLP-1 / metabolic Appetite, glucose, and cardiometabolic signaling FDA-approved products exist for specific indications Tirzepatide GIP/GLP-1 / metabolic Appetite, glucose, and metabolic signaling FDA-approved products exist for specific indications Retatrutide Triple agonist / metabolic GLP-1, GIP, and glucagon receptor signaling Investigational BPC-157 Tissue-repair research Gastrointestinal, tendon, and angiogenesis pathways Research-only
Is compounded semaglutide dangerous
How Lifestyle Support Changes Results Neither medication should be viewed as a replacement for lifestyle support
PMID 29364588
10.1056/NEJMoa2306963 [DOI] [PubMed] [Google Scholar] 79